Dr. James O'Connell has 37 years experience in the Pharmaceutical Industry. Having joined UCB (formerly Celltech) in 1986, he helped to establish the NCE screening group. Following his work on kinases he chaired the first IIR kinase workshop on screening methodologies.
As a core member of the global small molecule Technology support group and the HTS cross-site team he played a leading role in identifying and testing new screening platforms for UCB. He became Head of Biomolecular Sciences based in Slough, where his group was responsible for assessing new technologies, developing medium throughput and HTS screens for hit discovery and providing kinetic and mechanistic data for hit optimization.
Latterly, his work has focused on challenging protein: protein interactions and in particular their inhibition by fragments. Set the task of finding small molecule inhibitors for TNF, he successfully led such a team in the discovery and development of molecules that targeted this protein. He continues to work in this area applying the knowledge gained from this protein to other protein: protein interactions.